Halozyme Therapeutics
Yahoo Finance • 8 months ago
Halozyme to Report First Quarter 2024 Financial and Operating Results
SAN DIEGO, April 23, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its first quarter 2024 financial and operating results on Tuesday, May 7, 2024, following the close of tradin... Full story
Yahoo Finance • 11 months ago
Halozyme Announces argenx Received Approval in Japan for VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Co-Formulated with ENHANZE® for Generalized Myasthenia Gravis
VYVDURA® provides patients with option for self-administration SAN DIEGO, Jan. 18, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that argenx received approval from Japan's Ministry of Health,... Full story
Yahoo Finance • 11 months ago
Halozyme Announces Takeda Receives FDA Approval for HYQVIA® Co-formulated with ENHANZE® as Maintenance Therapy in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
SAN DIEGO, Jan. 16, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Takeda received U.S. Food and Drug Administration (FDA) approval for HYQVIA® [Immune Globulin Infusion 10% (Human)] co-fo... Full story
Yahoo Finance • last year
Halozyme to Present at Upcoming Investor Conferences
SAN DIEGO, Nov. 27, 2023 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that members of the senior leadership team are scheduled to present and host investor meetings at the following investor confe... Full story
Yahoo Finance • last year
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q3 2023 Earnings Call Transcript
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q3 2023 Earnings Call Transcript November 6, 2023 Halozyme Therapeutics, Inc. beats earnings expectations. Reported EPS is $0.75, expectations were $0.71. Operator: Hello and welcome to the Haloz... Full story
Yahoo Finance • last year
Halozyme and Acumen Pharmaceuticals Enter Global Collaboration and Non-Exclusive License Agreement for the ENHANZE® Technology in Alzheimer's Disease
Acumen represents thirteenth license partner for ENHANZE® Alzheimer's disease is a large and expanding market opportunity SAN DIEGO, Nov. 6, 2023 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced a global collabo... Full story
Yahoo Finance • last year
12 Cheap Biotech Stocks Smart Investors Are Piling Into
In this piece, we will take a look at 12 cheap biotechnology stocks that smart investors are piling into. If you want to skip our introduction to the biotechnology industry and how it might be affected by recent economic and stock market t... Full story
Yahoo Finance • last year
Should You Hold Halozyme Therapeutics (HALO)?
Carillon Tower Advisers, an investment management company, released its “Carillon Eagle Small Cap Growth Fund” first quarter 2023 investor letter. A copy of the same can be downloaded here. In the first quarter, small-cap stocks performed... Full story
Yahoo Finance • last year
Argenx's Vyvgart Hytrulo Becomes First FDA Approved Subcutaneous Option For Generalized Myasthenia Gravis
The FDA has approved Argenx SE's (NASDAQ: ARGX) Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc), an injection for subcutaneous (SC) use for generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine recepto... Full story
Yahoo Finance • 2 years ago
Those who invested in Halozyme Therapeutics (NASDAQ:HALO) five years ago are up 80%
While Halozyme Therapeutics, Inc. (NASDAQ:HALO) shareholders are probably generally happy, the stock hasn't had particularly good run recently, with the share price falling 19% in the last quarter. On the bright side the returns have been... Full story
Yahoo Finance • 2 years ago
Dow Jones Nears Session Highs; Cathie Wood Starts New Crypto Fund Amid Banking Crisis
The Dow Jones Industrial Average rose 1% in late trading Thursday after a bullish price reversal in the major indexes. Intel was the Dow's clear leader of the day with a hefty 5% gain. Chip leader Advanced Micro Devices was a big contribut... Full story
Yahoo Finance • 2 years ago
Dow Jones Rises Even As Fed's Pivot Remains Uncertain; Health Care Stocks Fall On New Medicare Plan
The Dow Jones Industrial Average rose by 1% in afternoon trading Thursday after a bullish price reversal in the major indexes. Intel was the Dow's clear leader of the day with a hefty 6% gain. Beleaguered First Republic Bank and chip leade... Full story
Yahoo Finance • 2 years ago
Is Halozyme Therapeutics (HALO) a Growing Stock to Invest In?
Carillon Tower Advisers, an investment management company, released its “Carillon Eagle Small Cap Growth Fund” fourth quarter 2022 investor letter. A copy of the same can be downloaded here. Small-cap stocks posted solid returns in the fou... Full story
Yahoo Finance • 2 years ago
Multiple Reasons For the Outperformance of Halozyme Therapeutics (HALO)
Bernzott Capital Advisors, an investment management firm, published its “US Small Cap Value Fund” fourth-quarter 2022 investor letter, a copy of which can be downloaded here. In the fourth quarter, the fund delivered a 10.36% net return co... Full story
Yahoo Finance • 2 years ago
Stock Market Rally Roars Higher On Cooling Inflation; Bitcoin, Meta, Tesla In Focus: Weekly Review
The stock market rally soared this week on a tame CPI inflation report. Bitcoin hit a two-year low while Meta and Tesla were in focus. Continue reading... Full story
Yahoo Finance • 2 years ago
Halozyme Therapeutics (NASDAQ:HALO) delivers shareholders solid 31% CAGR over 5 years, surging 6.7% in the last week alone
The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put in. But on the bright side, you can make far more than 100% on a really good stock. For example, the Halozyme Therapeutic... Full story
Yahoo Finance • 2 years ago
Dow Jones Futures Fall After Techs Lead Stock Market Rebound; Investors See End To Fed Rate Hikes
Apple and other techs led a big rally off morning lows as oil prices and bond yields dived. Markets see Fed rate hikes ending this year.... Full story
Yahoo Finance • 2 years ago
Dow Jones Futures: Techs Lead Stock Market Rebound; Investors See End To Fed Rate Hikes
Apple and other techs led a big rally off morning lows as oil prices and bond yields dived. Markets see Fed rate hikes ending this year.... Full story
Yahoo Finance • 3 years ago
Hart-Scott-Rodino Waiting Period Expires for Halozyme's Acquisition of Antares Pharma
SAN DIEGO, May 12, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the "HSR Act"), applicable... Full story
Yahoo Finance • 3 years ago
Antares Pharma to be acquired by Halozyme in $960M deal
Antares, which was originally founded in Exton, is a specialty pharmaceutical company that develops, manufactures and commercializes therapeutic products using its advanced drug delivery systems.... Full story
